XERS vs ZYME Stock Comparison
XERS currently leads ZYME in this stock comparison, with AIQ scores of 78 vs 68. The clearest difference is momentum, while ZYME has the stronger risk resilience profile.
What is the main difference between XERS and ZYME?
XERS leads the current stock comparison as Xeris Biopharma Holdings, Inc., with the clearest separation coming from momentum and the broader AIQ evidence mix.
AlgovestIQ AIQ Comparison
Xeris Biopharma Holdings, Inc. vs Zymeworks Inc.
XERS leads
XERS leads by 10 AIQ points, primarily on Momentum and Quality, but the lead has narrowed from 25 points over 30 sessions. Wall Street currently favors ZYME on target upside.
Fragile: 2 of 6 evidence groups support XERS, its lead is narrowing, and its current signal state is conflicted.
Xeris Biopharma Holdings, Inc.
Zymeworks Inc.
The Algovestiq AIQ Score currently favors XERS over ZYME, 78 versus 68 as of Nov 15, 2026. XERS's advantage is driven primarily by stronger momentum and quality, while ZYME holds the stronger risk resilience profile. XERS also shows the stronger technical structure relative to its 50-day moving average, though analyst target upside currently favors ZYME. 2 of 6 covered evidence groups favor XERS today, and the comparison is rated Fragile on stability: only 2 of 6 covered evidence groups agree. XERS lead: Weakening — the AIQ differential moved from 25 to 10 points over 30 sessions.
Compare Xeris Biopharma Holdings, Inc. and Zymeworks Inc. across the Algovestiq AIQ Score, valuation, quality, momentum, risk, technicals and analyst expectations.
Performance over time
Price return from daily closes; distributions are not included.
Price return comparison
Growth of $10,000, price only
Split-adjusted closes only. Distributions are excluded, which understates the return of any fund or stock that pays them.
Compare XERS and ZYME against another ticker
Open a multi-ticker workspace without changing this focused pair page.
AIQ Factor Divergence
Where the two separate, on the four dimensions behind the AIQ Score. Bars read outward from a shared zero: further from the centre is a wider gap.
- Momentum98 vs 78XERS +20
- Quality71 vs 62XERS +9
- Risk Resilience55 vs 61ZYME +6
- Value68 vs 66Even
2 of 6 evidence groups favor XERS. XERS’s edge is concentrated in momentum and quality; ZYME keeps a meaningful risk resilience edge.
What changed since the last close
Latest scored session 2026-11-13, compared against the prior scored session 2026-11-12.
Largest factor move: Value +1
No signal started or stopped since the prior session; its 9 active signals are unchanged.
Largest factor move: Risk Resilience +4
New signals
- Low Volume Rally Warning — bearish, volume, short horizon (0.56x)
XERS's lead narrowed by 1 AIQ point in the latest session.
Deeper signal detail for each name lives on its own signals page — XERS and ZYME both carry a full feed there.
The central trade-off
XERS (Xeris Biopharma Holdings, Inc.): the stronger current systematic profile, led by momentum and quality.
ZYME (Zymeworks Inc.): the counter-case, on risk resilience, fundamentals, analyst expectations.
The AIQ Score and Wall Street therefore point in different directions on this pair.
Which one fits your objective
The same two names rank differently depending on what you are optimizing for. All six reads are shown at once — none of them is hidden behind a toggle.
Balanced
XERSXERS on the overall AIQ Score, which weights Quality and Value most heavily.
Growth
XERSXERS on combined revenue and EPS growth.
Value
EvenThe two are level on Value.
Momentum
XERSXERS on the Momentum factor, by 20 points.
Lower downside
ZYMEZYME on Risk Resilience, by 6 points.
Analyst upside
ZYMEZYME on implied upside to the consensus price target.
AIQ vs Wall Street
The model and the Street disagree here: AIQ favors XERS, analyst targets favor ZYME. That disagreement is the most useful thing on this page.
| Measure | XERS | ZYME | Note |
|---|---|---|---|
| Implied upside to target | -10% | +62.3% | ZYME has more room |
| Target dispersion | +13.3% | +54% | Lower is tighter analyst agreement |
| Consensus | Buy | Buy | Context, not a primary driver |
| Analysts covering | 7 | 14 | Higher coverage generally improves confidence |
The two are measuring different things. The AIQ Score reads current fundamentals, valuation, trend and risk; analyst targets price forward expectations. A divergence of this kind is either a contrarian opportunity or a sign the model is missing something already priced in — it is worth resolving before acting on either.
Analyst targets are expectations, not predictions. Dispersion matters as much as the midpoint.
AIQ Agreement Matrix
2 of 6 covered evidence groups favor XERS. A wide gap backed by one group is a weaker case than a narrow gap backed by five.
| Evidence group | Favors | Reading |
|---|---|---|
| AIQ Score | XERS | 78 vs 68 |
| Fundamentals | ZYMEon balance | revenue growth 16.4% vs 54.9%; EPS growth 133.3% vs 4.9%; TTM ROE 23.1% vs 67.3%; gross margin 84.4% vs 98.3%; operating margin 12.7% vs 16.6% — ZYME takes 4 of 5 decided legs, not all of them |
| Valuation | Even | Value 68 vs 66 |
| Technicals | XERS | Price vs 50-day 60.1% vs -4%; vs 200-day 112.8% vs 2.8% |
| Risk Resilience | ZYME | Risk Resilience 55 vs 61 |
| Analyst expectations | ZYME | Target upside -10% vs 62.3% |
✓ agrees with the overall verdict · ✕ points the other way. Groups marked “not covered” lack data on one or both of XERS and ZYME and are excluded from the count.
AIQ Decision Stability
The conclusion is sensitive to small changes. Treat the lead as provisional and watch the flip conditions below.
- The AIQ gap is moderate at 10 points.
- Only 2 of 6 covered evidence groups agree. (argues the conclusion is provisional)
- The leader's advantage has been narrowing. (argues the conclusion is provisional)
- The leader is throwing conflicting signals. (argues the conclusion is provisional)
Stability combines the score gap, how broadly the evidence agrees, how steady the lead has been across daily snapshots, the current signal state on both names, and analyst dispersion on XERS.
How the comparison changed
120 daily snapshots · May 27 – Nov 13XERS lead: Weakening — the AIQ differential moved from 25 to 10 points over 30 sessions.
- Today
- XERS +10
- 78 vs 68
- 7 sessions ago
- XERS +18
- 77 vs 59
- 30 sessions ago
- XERS +25
- 76 vs 51
- 90 sessions ago
- XERS +21
- 71 vs 50
The lead changed hands once in this window, most recently on Jun 2 when XERS moved ahead of ZYME.
AIQ Signal Divergence
Only the signals that bear on the head-to-head. A conflicted name is carrying bullish and bearish rules at the same time — the technical evidence is not pointing one way.
6 bullish / 1 bearish / 2 neutral, conflicted
Only XERS
- 52-Week High Proximity — bullish, risk_regime, long horizon (0.7%)
- ADX Trend Strengthening — neutral, trend, medium horizon
- Keltner Channel Breakout — bullish, volatility, short horizon
- RSI Overbought — bearish, momentum, short horizon
- TRIX Bullish Signal — bullish, momentum, short horizon
- Uptrend Structure Active — bullish, trend, long horizon
2 bullish / 2 bearish / 2 neutral, conflicted
Only ZYME
- ADX Trend Weakening — neutral, trend, medium horizon
- Low Volume Rally Warning — bearish, volume, short horizon (0.56x)
- MACD Histogram Expanding Bearish — bearish, momentum, short horizon
Both carry 3 more signals that do not separate them: Golden Cross Active, ATR Expansion - Breakout Mode, EMA Ribbon Expansion Bullish.
XERS leads the comparison while carrying a conflicted signal state, which is one reason the stability rating is not higher.
Price vs model alignment
Whether the latest session's price move confirms what the model did over the same session, or contradicts it.
Neither the price nor the AIQ Score moved enough in the latest session to confirm or contradict the other (price +0.06%, AIQ +1 points).
Price is down while the AIQ Score moved up 2 points over the same session — price and model disagree (price -0.87%, AIQ +2 points).
What would flip this result
A state, not a forecast. These are the specific, observable changes that would reverse the verdict — not a price prediction.
- 1ZYME closes the Momentum gap — currently 20 points behind, the largest single contributor to XERS's edge.
- 2ZYME's Low Volume Rally Warning resolves — a bearish volume rule currently active against it.
- 3XERS's conflicting signal state resolves bearish — it currently carries 6 bullish and 1 bearish rules at once.
- 4The narrowing continues — the lead has already given back 15 points over 30 sessions, and a further 10-point move would eliminate XERS's advantage entirely.
The full evidence
Every number behind the verdict. The leader is called above each group so you are not left to solve it from the table.
Fundamentals
ZYME leads on balance| Metric | XERS | ZYME |
|---|---|---|
| Revenue growth (YoY) | 16.4% | 54.9% |
| EPS growth (YoY) | 133.3% | 4.9% |
| Gross margin | 84.4% | 98.3% |
| Operating margin | 12.7% | 16.6% |
| Return on equity (TTM) | 23.1% | 67.3% |
| Debt to equity | 4.63 | 2.52 |
Performance
XERS leads 6 of 6 windows| Metric | XERS | ZYME |
|---|---|---|
| 1 week (5 sessions) | 9.6% | -11.4% |
| 1 month (20 sessions) | 61.6% | 4.8% |
| 3 months (63 sessions) | 95.5% | 3.7% |
| 6 months (126 sessions) | 167% | 9.7% |
| Year to date | 112.2% | -0.3% |
| 1 year (252 sessions) | 119.5% | 35.5% |
Technicals
XERS has the stronger structure| Metric | XERS | ZYME |
|---|---|---|
| RSI (14) | 85.4 | 42 |
| ADX (14) | 47 | 23.8 |
| Price vs 50-day | 60.1% | -4% |
| Price vs 200-day | 112.8% | 2.8% |
| Volatility (1M, annualized) | 110.3% | 63.1% |
Risk
ZYME is the more resilient| Metric | XERS | ZYME |
|---|---|---|
| Beta | 0.07 | 0.78 |
| Sharpe ratio | 1.67 | 0.84 |
| Sortino ratio | 2.99 | 1.39 |
| Max drawdown | -34.9% | -23.6% |
| Current drawdown | 0% | -16.6% |
| Annualized volatility | 57% | 54% |
| Value at risk (95%) | -4.3% | -4.1% |
Straight answers
Each answer is regenerated from the current snapshot, not written once and left to age.
Which is better, XERS or ZYME?
On the Algovestiq AIQ Score, XERS is the stronger of the two as of Nov 15, 2026, scoring 78 against ZYME's 68. The edge comes from momentum and quality. ZYME is not without a case — it holds the better risk resilience profile, which matters more if that is the objective you are optimizing for. This is a systematic score, not a recommendation: it ranks the two on the same evidence, it does not know your holding period or tax position.
Is XERS or ZYME the better buy right now?
XERS carries the stronger systematic profile as of Nov 15, 2026, and the comparison is rated Fragile — 2 of 6 covered evidence groups agree. A Fragile rating means the conclusion is sensitive: only 2 of 6 covered evidence groups agree. Treat the lead as provisional.
Why does the AIQ Score favor XERS over ZYME?
The composite weights Quality, Value, Momentum and Risk Resilience. XERS leads Momentum by 20 points; XERS leads Quality by 9 points; ZYME leads Risk Resilience by 6 points. Where the two split, the factor with the larger weight carries the result.
Which has more analyst upside, XERS or ZYME?
Analyst price targets imply -10% upside for XERS and +62.3% for ZYME, so the Street currently favors ZYME. That points the opposite way to the AIQ Score, which favors XERS. The two are measuring different things: the model reads current fundamentals, valuation, trend and risk; the Street is pricing forward expectations. A divergence of this kind is either a contrarian opportunity or a sign the model is missing something the analysts have already priced — it is the single most useful row on this page to investigate. Analyst targets are expectations, not predictions, and dispersion matters as much as the midpoint.
Which is better value, XERS or ZYME?
Neither name separates on the peer-relative Value factor. The two are level on Value. The Value factor reads valuation relative to sector peers and to the company's own fundamental quality, so it is not the same as simply having the lower multiple.
Which has stronger growth, XERS or ZYME?
XERS on combined revenue and EPS growth. Growth here is measured on reported revenue and earnings, not on forward estimates — it describes what the businesses have delivered, not what the Street expects next.
Which has stronger momentum, XERS or ZYME?
XERS on the Momentum factor, by 20 points. Momentum is one of the four weighted factors in the AIQ composite. It has documented persistence over three- to twelve-month horizons, which makes it a timing input rather than a reason to hold something indefinitely.
Which is riskier, XERS or ZYME?
ZYME is the more resilient of the two, so the other name carries the higher downside risk. ZYME on Risk Resilience, by 6 points. Risk Resilience is a weighted factor in the composite; position sizing usually responds to it more usefully than the buy/avoid decision does.
Is XERS more profitable than ZYME?
ZYME leads on the comparable margin measures — gross margin 84.4% vs 98.3%; operating margin 12.7% vs 16.6%; ttm roe 23.1% vs 67.3%.
Is XERS's lead over ZYME getting stronger or weaker?
XERS lead: Weakening — the AIQ differential moved from 25 to 10 points over 30 sessions. This is measured from 120 daily comparison snapshots between 2026-05-27 and 2026-11-13. The lead has changed hands once in that window, most recently on 2026-06-02, when XERS moved ahead of ZYME.
What would change the XERS vs ZYME verdict?
The result is a state, not a forecast, so it changes when the underlying evidence changes. Concretely: ZYME closes the Momentum gap — currently 20 points behind, the largest single contributor to XERS's edge; ZYME's Low Volume Rally Warning resolves — a bearish volume rule currently active against it; XERS's conflicting signal state resolves bearish — it currently carries 6 bullish and 1 bearish rules at once; the narrowing continues — the lead has already given back 15 points over 30 sessions, and a further 10-point move would eliminate XERS's advantage entirely.
What do the current signals say about XERS and ZYME?
XERS: 6 bullish / 1 bearish / 2 neutral, conflicted. ZYME: 2 bullish / 2 bearish / 2 neutral, conflicted. A conflicted state means bullish and bearish rules are active on the same name at once — the technical evidence is not pointing one way, and a decision taken on it carries more timing risk. The most decision-relevant rule on XERS is Golden Cross Active (bullish, long horizon). On ZYME it is Golden Cross Active (bullish, long horizon).
Compare XERS and ZYME with others
Continue your research
This page answers which of the two. These answer the questions on either side of it.
How this comparison is scored
The Algovestiq AIQ Score composites four factors — Quality, Value, Momentum and Risk, each carrying a fixed weight. Sentiment is reported separately as SentimentPulse and is not folded into the composite. Scores refresh every trading day, and this page regenerates from the latest snapshot rather than being written once.
The verdict names a leader, states how broadly six independent evidence groups agree, and rates how durable that conclusion is given the score gap, its recent trajectory and the current signal state on both names.
How to use side-by-side comparison →This comparison is informational and educational, not investment advice. AIQ scores update daily; re-check after earnings, guidance or macro data that materially changes either name’s factor profile.